VRAX · Virax Biolabs Group Ltd
United States · RS rating 47 · As of 2026-11-03
| Price | 1.06 USD |
|---|---|
| 1-day change | -3.6% |
| RS rating (overall / 1M / 3M / 12M) | 47 / 3 / 5 / 93 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 22 / 42 / 22 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +83.3% |
| Market cap (USD) | $1.2M |